RECRUITINGINTERVENTIONAL

Genetic Variation in TRAF3IP2 (rs13190932)

Genetic Variation in TRAF3IP2 (rs13190932) and Its Association With Psoriasis, Psoriatic Arthritis, and Treatment Outcome With Methotrexate

About This Trial

Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population. It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals. The Pathogenesis of PsA involves a complex interplay of genetic, immunological, and environmental factors.Genetic studies have identified several susceptibility loci, including HLA-Cw6 and IL23R, which are shared with psoriasis. Additionally, the presence of certain alleles, such as HLA-B27, is associated with a more severe disease course and a higher likelihood of axial involvement.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients aged 18 -70years . - the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI \> 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) diagnosed by the Dermatologist or the Rheumatologist. - Willingness to participate: Signed willing to sign a consent form. - Initiating methotrexate (MTX) therapy: For prospective cohort. - Availability for follow-up: Patients must be willing and able to attend scheduled visit. Who Should NOT Join This Trial: - Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus). - Pregnancy and lactation. - Patients currently undergoing immunosuppressive or systemic therapies. - Patients with known genetic disorders affect immune system function. - Patients with liver or kidney impairment. - Patients with allergy or contraindication to methotrexate. - Patients with active or uncontrolled infections, including chronic infections like tuberculosis. - Previous genetic analysis Patients who have previously undergone genetic analysis for the TRAF3IP2 gene polymorphism (rs13190932). Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Patients aged 18 -70years . * the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI \> 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) diagnosed by the Dermatologist or the Rheumatologist. * Willingness to participate: Signed informed consent. * Initiating methotrexate (MTX) therapy: For prospective cohort. * Availability for follow-up: Patients must be willing and able to attend scheduled visit. Exclusion Criteria: * Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus). * Pregnancy and lactation. * Patients currently undergoing immunosuppressive or systemic therapies. * Patients with known genetic disorders affect immune system function. * Patients with liver or kidney impairment. * Patients with allergy or contraindication to methotrexate. * Patients with active or uncontrolled infections, including chronic infections like tuberculosis. * Previous genetic analysis Patients who have previously undergone genetic analysis for the TRAF3IP2 gene polymorphism (rs13190932).

Treatments Being Tested

DRUG

Methotrexate

Assessing the response of psoriasis and psoriatic arthritis to Methotrexate. and also Assessing the pharmacogenetic association between TRAF3IP2 ( rs13190932 ) gene Polymorphism in psoriatic and psoriatic arthritis patients taking Methotrexate.

Locations (1)

Qena Hospital

Qina, Egypt